Aditum Bio and Leads Biolabs have partnered to establish Oblenio Bio, focusing on the development of a tri-specific T-cell engager antibody for autoimmune diseases.
Information on the Target
Aditum Bio, a California-based venture capital firm, has announced the launch of a new biotechnology company named Oblenio Bio in collaboration with Leads Biolabs, a company based in China. Oblenio Bio is established with the aim of developing a tri-specific T-cell engager antibody designed to combat autoimmune diseases. This initiative is part of Aditum's strategy of spinning out promising clinical assets into dedicated firms.
Leads Biolabs is providing Oblenio with an exclusive option to develop and commercialize its candidate, LBL-051, on a global scale. The partnership signifies a significant advancement in biotechnology, especially in the treatment of autoimmune disorders, as the developed antibody targets multiple cells associated with such diseases.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The biotechnology industry in China has seen remarkable growth in recent years, becoming a global leader in biopharmaceutical research and development. The country’s government has introduced various policies that encourage innova
Similar Deals
VivaVision → Jiangxi Shanliang Pharmaceutical Co., Ltd.
2024
Aditum Bio
invested in
Oblenio Bio
in 2023
in a Joint Venture deal